Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Biogen Inc.

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

BIIB●NASDAQ
HealthcareDrug Manufacturers - General
$216.78
$2.43(1.13%)
U.S. Market opens in 64h 14m

Biogen Inc. (BIIB)

Meyka AI Score

Z

Key Financials

Market Cap32B
P/E Ratio38.10
EPS (TTM)$15.84
ROE0.05%
Fundamental Analysis

AI Price Forecasts

1 Month$220.69
3 Months$217.94
1 Year Target$136.62

BIIB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Biogen Inc. (NASDAQ: BIIB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Biogen Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BIIB on the NASDAQ shows an RSI of 59.36, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $136.62 for the NASDAQ listing.

Key metrics behind Biogen Inc.'s NASDAQ-traded stock include a P/E ratio of 38.10 and a market capitalization of 32B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BIIB on the NASDAQ.

Price Performance (NASDAQ: BIIB)

1-Day Change
1.13%
5-Day Change
3.22%
1-Month Change
6.70%
3-Month Change
14.41%
6-Month Change
12.89%
Year-to-Date (YTD) Change
23.18%
1-Year Change
55.82%
3-Year Change
-18.22%
5-Year Change
-37.42%
All-Time (Max) Change
6836.96%

Contact Information

https://www.biogen.com
617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

75,000 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions